Difference with ACR is that it was using a previously used drug that has been around for a long time and very well studied , but utilising a difference administration method so the chances of it succeeding were much higher than trof
The risk with partnering trof is phase 3 fail - we get stuff all
They would definitely reapply for BT - I look at the first application as a blind test to feel out FDA. They would have learnt a lot from that . Mistake was - they should have kept in house!!
At end of the day we can all speculate time will tell but none the less this is very exciting for all . Regardless we have 2 X positive p2 - that is worth a lot more then what we are siting at regardless of external market conditions
Dare I mention the words..., page-26
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |